Pharmaleaders Visionary Pharma Entrepreneur 2014 Awardee Dilip Surana led Microlabs aims $1 billion mark by 2016
Pharmaleaders Visionary Pharma Entrepreneur 2014 Awardee Dilip Surana led Microlabs aims $1 billion mark by 2016
Bangalore based Top Pharma Major Microlabs known as Dolo Maker plans to scale new heights under Dilip Surana’s Visionary & Commanding Leadership, Dilip Surana to receive “Visionary Entrepreneur of the Year Award” at Pharma Leaders 2014 Historic Meet
Sunday,7th December 2014, Mumbai, Maharashtra : It is widely believed that the consolidations in the Indian pharma sector is likely to continue, particularly among generic drug players and will drive shareholder value going forward.India-based pharmaceutical companies have majorly been absent from much of the recent M&A activities, partly because of their healthy growth outlooks. The global pharmaceutical industry will continue to undergo a pace of rapid consolidation to drive shareholder value; particularly in the case of companies seeking new growth platforms, against the backdrop of patent expirations.With many drugs going off patent in the US, Indian pharma companies would continue to experience strong growth in American market, indian pharma companies would continue to experience strong growth in the US over the medium-term. This would be driven by the sizable generic opportunity (drugs with brand value of $25-30 billion are expected to face generic competition) over the next 2-3 years.
As one of the recently industrialized nations, India has a fast-growing economy as well as an ever-expanding, ever-urbanized population, however its healthcare system still has a lot of potential for development. To Western readers, analyzing a healthcare system in the East seems daunting. It takes some of us decades to master an understanding of the healthcare system of our origin country. Nevertheless, there are several methods to approaching another country’s system. These include the exposition of some invariant principles that apply across various contexts, the application of existing frameworks for healthcare system analysis, appraisal of the major transitions underway in the country, and an analysis of the country’s public health issues. India faces challenges in pursuing each of these goals. With regards to cost, at least 70% of all healthcare is frequently financed out-of-pocket by the population. There is little health insurance or other forms of risk pooling, little regulation and accountability of providers, and a predominance of fee-for-service payment, all of which are associated with high costs. There is also questionable efficiency of much of the state healthcare system, and a great distrust of the public sector. Against the backdrop of the above challenges, Pharmaleaders has lined up top industry experts, Pharma Academia, Ministry Officials, Government Representative, Policy Makers & Medical Professionals under one platform both in india & abroad to debate & deliberate the complex issues of the industry & give a meaningful discussion on the Brand India & Make In India concept. More than 300 professionals will be participating the mega event where professionals from Middle East, Africa, Europe, Lation America will also be attending.The historic 7th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2014 to be held in a uniquely positioned full day program encompassing two themes “Make In India – Healthcare Reforms , Insurance,Innovations,Investments & Infrastructure” & Empowering India’s Developing Healthcare System – Investing the Healthcare Solutions of Tomorrow in difficult Times at the Sahara Star, Mumbai International Airport in Mumbai, India, on December,26th , 2014. This historic Summit is supported by the Government of India at the Centre & is actively supported by the Ministry of Health & Family Affairs, Govt of India, Ministry of Commerce Pharmaceuticals , Government of india & host of other trade bodies.
Commenting on the Award Selection to Dilip Surana as “Visionary Entrepreneur of the Year Award” at pharmaleaders 7th Award Night, Satya Brahma, Chairman & Editor-In-Chief of Network 7 Media Group said “Pharma Leaders™ , asia’s biggest media in healthcare communications in association with Network 7 Media Group undertook the gigantic task of identifying the Leader in Healthcare Innovations as it has been doing for years. The Primary factor that propelled the Jury is to look at the forward looking vision of the company coupled with the risk taking abilities & the visionary Leadership of steering the company in the complex business of healthcare where each day we are witnessing new competition, bigger challenges & ability to stay ahead of competition. With a modest beginning as a pharmaceutical distributor in 1973 by Dilip Surana’s late father Shri G.C.Surana, the meteoric rise of Microlabs as a Leading player in pharmaceutical business with a formidable basket of top products enjoying the strong patronage of medical doctors can be attributed to the fact that how Dilip spearheaded the strategy to make it big. Today Microlab is ranked among the top 20 pharma companies in the country.Indeed Microlabs has become one of the top 5 pharma players in the diabetes sector in India. Hailing from a village near Jodhpur in Rajasthan, the low profile Dilip Surana together with brother Anand Surana have propelled the growth engine with tremendous speed & dedicated mindset & your initiatives in the social sector is also a case to reckon with as Dilip’s efforts to help the marginalized sections of the society is a sign of a true global Leader. Pharma Leaders™ salute the deep commitment to bring cheers in the humanity & the visionary commanding Leadership in taking Microlabs to the crescendo of success & achievements”.
The Award ceremony is scheduled at 07.00 PM on 26th December 2014 onwards at the Grand Jade Room of Hotel sahara Star, Mumbai, India. Like every year, this will be attended by more than 300 power packed Healthcare Leaders in all disciple in the glittering award night followed by cocktail & Dinner
Mr. Dilip Surana son of Late Shri G. C. Surana (Founder of Micro Labs Limited) joined the family business in 1985 at a young age of 21 years, and rapidly absorbed the nuances of Corporate Management that grew the company rapidly into a global pharmaceutical enterprise specializing in life saving medicines. His early years in industry were marked by distinguished accomplishments and thus steering Micro Labs among the top ranking companies in the pharma sector. The AWACS ranking for the company has improved from over 100 in 1985 to 18 as on 2014.
Under his leadership, the company established world-class state-of-the-art research and manufacturing facilities covering Active Pharmaceutical Ingredients (APIs) and finished dosage forms as well as infrastructure for new drug discovery. He instilled the most stringent quality standards in his pharmaceutical enterprise. As a result, Micro Labs has to its credit, all the international regulatory approvals including US FDA, UK MHRA, Australian TGA etc., reflecting the high standards of quality and regulatory compliance of research and manufacturing facilities.
Dilip Surana pioneered the concept of specialty – wise focused divisions in the Indian Pharmaceutical Industry and established various divisions that cater to special therapeutic segments in chronic disease management.
- Carsyon – Cardicare specialty division in 1994
- Synapse – Neurology Psychiatry division in 1995
- Vision – Ophthalmology division in 1998
- Gratia – Dermatology Division in 1998
- Diabetic Task Force Diabetology division in 2005
- Foresee – Nephrology Division in 2008
- Micro Critical Care – Critical Care Division 2013
He is a regular participant in various international seminars and summits relating to Pharma industry. He is instrumental in inducting Senior Pharma veterans in the company, to bring in the much needed professionalism in the company. Recognizing the dynamism and contribution of Mr. Dilip Surana to the Pharmaceutical Industry, he has been honored as the ‘Dynamic Entrepreneur of the year 2010’, honoured as the ‘Great Son of karnataka’ by Governor of Karnataka his excellency HR Bhardwaj in 2011, honoured as ‘Most Dynamic Entrepreneur of the Year’ 2013 and ‘Entrepreneur of the year’ 2014.
Micro Labs Limited is a multi-faceted healthcare organization with a proficient marketing team, state-of-the-art manufacturing facilities and R&D centres that are at par with international standards. All this, robustly backed by a strong distribution network and path-breaking research work has placed us amongst India’s fast growing transnational healthcare organizations. Under the able leadership of Mr. Dilip Surana (Chairman & Managing Director) and Mr. Anand Surana (Director), Micro’s brand portfolio includes some of the topmost brands in various specialties like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain, etc. Amidst our proud achievers is Dolo, an award-winning brand highly prescribed for fever management. Micro Labs has been ranked among top 17 (as per SMSRC July-Aug’14) in prescriptions and 19 in sales (as per AWACS Sept’14) in India. The group has its presence in over 30 countries, with ground level operations in 15 countries, exporting all major dosages in every therapeutic segment. Being one of the leading Indian healthcare providers in India, Micro Labs aims to be a prominent pharmaceutical player in regulated and non-regulated markets across the globe.The company is also at the forefront in social contribution, striving to be a model corporate citizen in terms of Environmental Protection & Social Initiatives with significant contributions in the areas of education and health.Micro Labs is poised to achieve unparalleled status in the global pharmaceutical industry. Backed by a profound and resolute vision, we now have our eyes set on attaining the $1 billion mark by 2016.
